Skip to Main Content

The Food and Drug Administration is bringing together a panel of outside experts to review a novel and controversial drug for treatment-resistant depression.

The FDA advisory panel meets on Nov. 1. Its charge: review the efficacy and safety of the experimental antidepressant medicine called ALKS 5461, developed by the biopharma company Alkermes (ALKS). After chewing over all the data, the experts on the panel will vote on a recommendation to approve ALKS 5461, or not.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.